Keynote SeriesPharmaceutical Technology and BioPharm International are sponsoring a Keynote Series session on strategies and innovations to reduce drug shortages and improve availability of medicines on the INTERPHEX 2016 Exhibit Hall Innovation Stage. Admission is free to any attendee with an exhibit hall pass.
Wednesday, April 27
1:30–3:15 pm
Strategies and Innovations to Reduce Drug Shortages and Improve Availability of Medicines
Aging facilities and equipment, inadequate operator training, a lack of quality control, tighter regulatory enforcement, and business decisions to eliminate unprofitable product lines contribute to ongoing shortages vital drug products. In this session, industry thought leaders will identify triggers for drug shortages, methods to avoid production line shutdowns and update facilities, and innovative industry efforts to fulfill demand for needed therapies. A Q&A session will follow the presentations.
1:30–2 pm
An Interdisciplinary Approach to Address Drug Shortages
The effects of drug shortages on patients, caregivers, hospitals, and medical professionals are often not observed or understood by the bio/pharmaceutical manufacturing segment. The implications of production and quality problems, as well as business decisions to limit or terminate production of needed but unprofitable drugs, are far-reaching. This presentation will explore alternative, innovative, and cost-effective ways to provide needed therapies to patients.
Speaker: Stephen P. Spielberg, MD, PhD, Industry Consultant, Secure Affordable Quality Supply
To register: http://www.interphex.com/pharmtech
Other presentations in this session:
2-2:30 pm
BARDA Innovation Initiatives in Medical Countermeasure Manufacturing
2:30-3 pm
Continuous Manufacturing for Rapid Process Development
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.